News

Merck has suspended patient enrollment in two Phase 3 clinical trials, KEYNOTE-183 and KEYNOTE-185, testing Keytruda (pembrolizumab) in combination with other therapies in patients…

Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study,…

Updated results from an ongoing Phase 1 clinical study of bb2121, an investigational therapy for the treatment of multiple…

An ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) multiple myeloma patients. The new anti-BCMA…

Oncology Venture has enrolled the first patient into a Phase 1/2 trial of its compound APO010 in multiple myeloma. Patients in the study will…

Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated…

The first research program dedicated to the early detection and prevention of multiple myeloma will  be under way soon, thanks to a $4 million Perelman Family…

Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab), according…

A Phase 2 trial has shown that Keytruda (pembrolizumab) increases the effectiveness of Pomalyst (pomalidomide) and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). The study…

Patients with advanced multiple myeloma who received three or more lines of therapy have shown promising safety and efficacy…